前列腺癌早期检测，版本 1.2014. NCCN 指南的特色更新。

Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.

机构信息

From UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Vanderbilt-Ingram Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Massachusetts General Hospital Cancer Center; The University of Texas MD Anderson Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Fox Chase Cancer Center; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; City of Hope Comprehensive Cancer Center; University of Washington/Seattle Cancer Care Alliance; Dana-Farber/Brigham and Women's Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Colorado Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Moffitt Cancer Center; Duke Cancer Institute; University of Alabama at Birmingham Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; St. Jude Children's Research Hospital/University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

出版信息

J Natl Compr Canc Netw. 2014 Sep;12(9):1211-9; quiz 1219. doi: 10.6004/jnccn.2014.0120.

DOI:10.6004/jnccn.2014.0120

PMID:25190691

Abstract

The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for men choosing to participate in an early detection program for prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Overall, the 2014 update represents a more streamlined and concise set of recommendations. The panel stratified the age ranges at which initiating testing for prostate cancer should be considered. Indications for biopsy include both a cutpoint and the use of multiple risk variables in combination. In addition to other biomarkers of specificity, the Prostate Health Index has been included to aid biopsy decisions in certain men, given recent FDA approvals.

摘要

美国国家综合癌症网络（NCCN）前列腺癌早期检测指南为选择参加前列腺癌早期检测计划的男性提供了建议。这些 NCCN 指南要点突出了最近的显著更新。总体而言，2014 年的更新代表了一组更精简和简洁的建议。专家组对开始进行前列腺癌检测的年龄范围进行了分层。活检的适应证包括一个临界点和多个风险变量的联合使用。除了其他具有特异性的生物标志物外，鉴于最近获得美国食品药品监督管理局（FDA）批准，前列腺健康指数也被包括在内，以帮助某些男性做出活检决策。